SNAP-8 (Acetyl Octapeptide-3)

SNAP-8 is a skincare peptide sold as a needle-free, “Botox-like” treatment for expression wrinkles (the lines that show up when you smile, frown, or squint). The basic idea is the same one behind its better-known cousin Argireline, and on paper it makes sense. The catch is that the human results behind SNAP-8 come from the manufacturer’s own small studies — most of which weren’t blinded (meaning the testers knew who got the product, which can bias the results). No independent blinded trial seems to exist. And there’s a nagging problem: the peptide may not even reach the spot in the skin its whole mechanism depends on.

What it is

SNAP-8 is a lab-made octapeptide — a short chain of eight amino acids (the building blocks of proteins), with chemical caps added on each end. Its INCI name (the standardized cosmetic-ingredient name) is Acetyl Octapeptide-3, and its trade name is SNAP-8. It was developed by Lipotec, now part of Lubrizol. It carries PubChem CID 71587832 (a database ID number), molecular formula C42H72N16O15S, and a molecular weight of about 1073 g/mol (PubChem lists 1073.2 g/mol).

It’s a stretched-out version of Argireline (Acetyl Hexapeptide-8), with two extra amino acids tacked on. Both SNAP-8 and Argireline are modeled on one end of a protein called SNAP-25, which is part of the machinery (the SNARE complex) your nerves use to release acetylcholine — the chemical signal that tells a muscle to contract — at the spot where a nerve meets a muscle (the neuromuscular junction).

The proposed mechanism aims at the same pathway botulinum toxin (Botox) works on, just from a different angle. By imitating SNAP-25, SNAP-8 is supposed to crowd out the real protein and slow the assembly of that signaling machinery. Less acetylcholine gets released, the facial muscle relaxes a little, and the expression wrinkles soften. The idea is that this effect is gentle and reversible — it just competes with the natural protein — rather than the permanent cutting action botulinum toxin uses. This mechanism has been described in the test tube for this family of peptides, but it has not been confirmed to actually happen in human skin for SNAP-8 specifically.

The claims

SNAP-8 is sold as a topical “active” ingredient (something added to a product to do a job), showing up in skincare formulas and as raw “research” or “cosmetic” powder. The headline pitch is “Botox-like” wrinkle reduction with no needles. The numbers you’ll see repeated everywhere are roughly a 35% wrinkle reduction (versus about 27% for Argireline), or “up to ~63% wrinkle-depth reduction at 28 days.” As you’ll see below, these figures come from the manufacturer’s own technical materials — not from independent trials.

What the evidence actually shows

The human data on SNAP-8 specifically is thin, and it isn’t independent. The widely quoted numbers trace back to Lipotec/Lubrizol’s own technical literature, including a small study of roughly 17 women that wasn’t blinded. INCIDecoder, an independent ingredient database, backs up that this study had about 17 people and showed 34.98% versus 27.05% (compared to Argireline) — and it points out plainly that, unlike the better-studied Argireline, SNAP-8 has no independent peer-reviewed (vetted by outside experts) confirmation, only “the manufacturer’s claim.” We could not find a single independent, peer-reviewed, blinded trial of SNAP-8 — including the split-face kind, where one side of the face gets the product and the other doesn’t, for a fair comparison. So treat the percentage claims as vendor data, not proven results.

There is some lab and delivery research, but it doesn’t show a real-world benefit. Baglamis, Feyzioğlu-Demir and Akgöl (Polymer Bulletin, 2023) ran a test-tube (in vitro) study using tiny particles (poly-HEMA-based nanoparticles) to release the peptide slowly and help it absorb better. That’s a study about how to package and deliver the ingredient — not a test of whether it works on people.

Getting the peptide into the skin is a real, unsolved problem. For the closely related parent peptide Acetyl Hexapeptide-8, a 2025 peer-reviewed review in the International Journal of Molecular Sciences found that the skin-penetration data conflicts wildly. One study reported about 30% crossing the skin barrier in the test tube, while another found only about 0.22% making it through the stratum corneum (the tough outermost layer of skin) — with none reaching the other side at all — and certain water-and-oil emulsion formulas delivered only about 2–3% after 8 hours. Most importantly, the review notes that no study in a living body (in vivo) has confirmed the claimed muscle-relaxing effect, calling that effect “largely hypothetical.” These peptides are big and water-loving (hydrophilic), so they don’t easily slip through intact skin — which knocks out the whole “it reaches the nerve-muscle junction” reasoning. And these same concerns apply at least as much to the larger SNAP-8.

The bottom line on the evidence: the underlying mechanism is believable and well-documented for this peptide family in cells and test tubes, but the case that SNAP-8 specifically helps real skin rests on small, manufacturer-funded studies that mostly weren’t blinded. There’s no independent confirmation that it meaningfully relaxes facial muscles in living skin. In short, the credible human evidence just isn’t there.

Legal and regulatory status

SNAP-8 is a cosmetic ingredient, nothing more. It’s sold as a topical skincare “active” and as raw “research” or “cosmetic” powder. It is not an approved drug, has no FDA drug approval, and isn’t a dietary supplement. In the EU it’s a registered cosmetic ingredient (INCI listed). Calling it “Botox-like” is a cosmetic marketing phrase, not a claim that it’s been proven equal to a drug — unlike the approved drugs in this general area, SNAP-8 has never gone through drug-approval trials.

On anti-doping: SNAP-8 is a topical cosmetic peptide with no reason to boost athletic performance. It is not named on the WADA Prohibited List (the banned-substance list for athletes). It doesn’t fall under the hormone and metabolic-modulator class (category S4, which covers AMPK activators such as AICAR) or the SARM provisions (under S1, anabolic agents). There’s no realistic way to use it for doping and no SNAP-8-specific entry to worry about. Athletes can still check any finished product through Global DRO, but there’s nothing list-specific to flag here.

Safety

Nothing in the literature points to a serious safety problem, but there’s also no solid, long-term, independent human safety data. As a low-strength topical cosmetic, it’s generally considered well tolerated. The issues that do come up are minor and not specific to this ingredient — things like local irritation or contact dermatitis (an allergic-type skin rash) that any leave-on serum can cause.

A few things are worth keeping in mind. Real products vary a lot in how much peptide they contain and how they’re formulated, and “research-grade” or DIY raw powder isn’t checked for purity or sterility. Because there isn’t strong independent proof it works, claims of Botox-equivalent results aren’t supported. And there’s no established safety or proven benefit for any injected use — SNAP-8 is a topical cosmetic only. None of this is medical advice.

Bottom line

SNAP-8 has a clever, Botox-inspired mechanism and a reasonable safety record when used topically at low strength. But the eye-catching wrinkle-reduction percentages come from the manufacturer’s own small, unblinded studies, no independent blinded trial seems to exist, and lab data on its close relative show these molecules barely get through intact skin — with no proof in a living body that they relax muscle. Think of SNAP-8 as a low-risk cosmetic ingredient whose “topical Botox” promise is unproven — not as a validated wrinkle treatment or a stand-in for injectable botulinum toxin.

Evidence grade: 1/10 · Unsupported.

Sources

• PubChem. Acetyl octapeptide-3 (CID 71587832; formula C42H72N16O15S, MW ~1073.2 g/mol).
• Baglamis S, Feyzioğlu-Demir E, Akgöl S. New insight into anti-wrinkle treatment: using nanoparticles as a controlled release system to increase acetyl octapeptide-3 efficiency (in vitro delivery study). Polymer Bulletin, 80:12659–12681, 2023.
• Quiñones OG, et al. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Int J Mol Sci, 2025 (PMID 40565185 / PMCID PMC12193160).
• INCIDecoder. Acetyl Octapeptide-3 (independent ingredient note on SNAP-8 efficacy claims).